ORIGINAL PAPER
A clinical characteristic of paediatric ulcerative colitis patients qualified for a Cyclosporin A therapy
Publication date: 2018-03-07
Pediatr Pol 2017;92(4):378-381
KEYWORDS
ABSTRACT
Background:
According to ECCO/ESPGHAN consensus for managing acute severe ulcerative colitis in children, Cyclosporin A remains a rescue therapy in acute steroid-refractory ulcerative colitis.
Aim:
To describe clinical features of children qualified for Cyclosporin A (CsA) treatment.
Material and methods:
It is a retrospective, single centre study. We describe a clinical characteristic of children who underwent CsA treatment in the course of ulcerative colitis (UC).
Results:
We evaluated 59 children's medical charts treated in our department with Cyclosporin A in the course of ulcerative colitis in years 2005–2015. There is a female predominance in the study (34/59). The median age at the diagnosis was 11.9 years, while the median age of the initiation of CsA 15 years. Ulcerative colitis had lasted on median 20 months when CsA was initiated. The median PUCAI score at the onset of CsA therapy was 50.00. Almost 80% of patients had a moderate/severe course.
Conclusion:
CsA was in our department the drug of choice in case of steroid refractory ulcerative colitis.
According to ECCO/ESPGHAN consensus for managing acute severe ulcerative colitis in children, Cyclosporin A remains a rescue therapy in acute steroid-refractory ulcerative colitis.
Aim:
To describe clinical features of children qualified for Cyclosporin A (CsA) treatment.
Material and methods:
It is a retrospective, single centre study. We describe a clinical characteristic of children who underwent CsA treatment in the course of ulcerative colitis (UC).
Results:
We evaluated 59 children's medical charts treated in our department with Cyclosporin A in the course of ulcerative colitis in years 2005–2015. There is a female predominance in the study (34/59). The median age at the diagnosis was 11.9 years, while the median age of the initiation of CsA 15 years. Ulcerative colitis had lasted on median 20 months when CsA was initiated. The median PUCAI score at the onset of CsA therapy was 50.00. Almost 80% of patients had a moderate/severe course.
Conclusion:
CsA was in our department the drug of choice in case of steroid refractory ulcerative colitis.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
